News coverage about Fibrocell Science (NASDAQ:FCSC) has trended somewhat positive on Sunday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fibrocell Science earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.9503402571486 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Fibrocell Science (NASDAQ FCSC) opened at $0.75 on Friday. Fibrocell Science has a fifty-two week low of $0.61 and a fifty-two week high of $4.64.
FCSC has been the topic of several research reports. Zacks Investment Research raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. HC Wainwright restated a “buy” rating and issued a $7.60 target price on shares of Fibrocell Science in a report on Thursday, October 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Fibrocell Science currently has an average rating of “Hold” and an average target price of $5.21.
In other news, major shareholder Randal J. Kirk acquired 2,727,273 shares of the stock in a transaction on Monday, December 11th. The stock was acquired at an average price of $0.77 per share, with a total value of $2,100,000.21. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.10% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/14/fibrocell-science-fcsc-getting-somewhat-positive-media-coverage-report-finds.html.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.